{
  "url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-no-3-order-1998/schedule",
  "json_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-no-3-order-1998/schedule.json",
  "legislation": "uksi/1998/2081",
  "legislation_title": "The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998",
  "legislation_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-no-3-order-1998",
  "path": "schedule",
  "kind": "schedule",
  "number": "THE",
  "heading": "ENTRIES INSERTED IN SCHEDULE 1 TO THE PRINCIPAL ORDER",
  "text": "Column 1\nColumn 2\nColumn 3\nColumn 4\nColumn 5\nSubstance\nMaximum strength\nRoute of administration, use or pharmaceutical form\nTreatment limitations\nMaximum quantity\nAloxiprin\n(1) 620 mg\n(1) Non-effervescent tablets and capsules\n(1) The quantity sold or supplied in one container or package shall not exceed 32\nThe quantity of non-effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100\n(2) All preparations other than non-effervescent tablets or capsules\nDiphenhydramine Hydrochloride\nAll preparations except liquid-filled capsules\nHydrocyanic Acid\nIbuprofen Lysine\nRheumatic and muscular pain, pain of non-serious arthritic conditions, backache, neuralgia, migraine, headache, dental pain, dysmenorrhoea, feverishness, symptoms of colds and influenza\nInternal\n(a) In the case of a prolonged release preparation 600 mg (MD) 1,200 mg (MDD)\n(b) in any other case 400 mg (MD) 1,200 mg (MDD)\nLevocabastine Hydrochloride\nEquivalent of 0.05 per cent Levocabastine\n(1) Nasal sprays\nFor the symptomatic treatment of seasonal allergic rhinitis\n(1) Container or package containing not more than 10 ml of medicinal product\n(2) Aqueous eye drops\nFor the symptomatic treatment of seasonal allergic conjunctivitis\n(2) Container or package containing not more than 4 ml of medicinal product\nNilutamide\nPhytomenadione\nAny use except the prevention or treatment of haemorrhagic disorders\nStrychnine Nitrate\nSulfabenzamide",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/1998/2081/schedule",
    "retrieved_at": "2026-10-29T11:20:27.921030+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}